{
  "docId": "019de517-75a1-7387-968b-d0dc513bf421",
  "docSlug": "e930bfcc8684afb6f5a4dd5442b5166d",
  "documentTitle": "Ocuphire Pharma | Investor Presentation Deck | 42 slides",
  "authorId": "ocuphire-pharma",
  "authorName": "Ocuphire Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 42,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 30,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de517-75a1-7387-968b-d0dc513bf421/29",
  "deckHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421",
  "deckJsonHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421.json",
  "deckAnchorHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.039,
        "w": 0.08,
        "x": 0.024,
        "y": 0.93
      },
      "kind": "image",
      "text": "Ocuphire",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "161f92fd-b208-41c9-9b6d-9f14d94a92c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.58,
        "w": 0.446,
        "x": 0.513,
        "y": 0.264
      },
      "kind": "list",
      "text": "APX3330 Safety Profile:\nLimited AEs, most mild in severity\nPruritis: Mild and resolved without APX3330 dose de-escalation or discontinuation\nAEs similar to or less than placebo\nFew serious treatment-related AEs, all unrelated to study medication\nNo ocular AEs other than expected DR progression\nLower incidence of clinical DR/DME worsening with APX3330\nPatients continued routine medications to manage their diabetes comorbidities",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6bdfed8-ff5e-4801-a452-5ceb8fb5a3e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.049,
        "w": 0.64,
        "x": 0.12,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "APX3330 SAEs: Dyskinesia, TIA, Chest pain\nPlacebo SAEs: Vertigo, Asthenia, Multiple organ dysfunction, Bradycardia, CAD, Cholelithiasis, COVID-19 pneumonia, Cellulitis, Respiratory failure, Skin ulcer, Peripheral embolism\nAEs → Withdrawal APX3330: Presyncope, Dyspnea; Placebo: DME (both eyes)\n*Preferred Term within Organ Class",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "787aa847-2297-41b7-a5f5-888a8aa226fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.73,
        "w": 0.439,
        "x": 0.068,
        "y": 0.168
      },
      "kind": "table",
      "text": "Placebo (n=52): Total AEs 120, #of Subjects with AEs 35 (67%), Treatment-related AEs 17 (14%), Serious AEs 11 (9%), Subjects Withdrawals Due to AEs 1 (2%), Deaths 1 (2%), Diabetic Retinal Edema 5 (10%), Diabetic Retinopathy 6 (12%), Vitreous detachment 3 (6%), Cataract 1 (2%), Pruritus 1 (2%), Rash 1 (2%), COVID-19 5 (10%). APX3330 (n=51): Total AEs 91, #of Subjects with AEs 29 (57%), Treatment-related AEs 14 (15%), Serious AEs 3 (3%), Subjects Withdrawals Due to AEs 2 (4%), Deaths 0 (0%), Diabetic Retinal Edema 2 (4%), Diabetic Retinopathy 1 (2%), Vitreous detachment 0 (0%), Cataract 3 (6%), Pruritus 6 (12%), Rash 3 (6%), COVID-19 1 (2%).",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5298352-8f5f-4490-82bf-3f8b2cf45a04",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.799,
        "x": 0.049,
        "y": 0.09
      },
      "kind": "title",
      "text": "Oral APX3330 Showed a Favorable Safety and Tolerability Profile Consistent with Prior Trials",
      "attrs": {},
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "817ce018-805d-49a1-a42e-35cd91e7a37a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.609,
        "x": 0.049,
        "y": 0.06
      },
      "kind": "title",
      "text": "ZETA-1: Treatment of Emergent Adverse Events",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22eabd32-4f73-4004-9d04-b96d0e928ff3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "7a84d56e-2cec-42eb-a807-99627abc95e5",
      "evidence": "table/data: Placebo (n=52): Total AEs 120, #of Subjects with AEs 35 (67%), Treatment-related AEs 17 (14%), Serious AEs 11 (9%), Subjects Withdrawals Due to AEs 1 (2%), Deaths 1 (2%), Diabetic Retinal Edema 5 (10%), Diabe",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 42,
      "from": 29,
      "beatId": "691510f1-c63c-46db-bda1-6d94434f6f9b",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 29-42 discuss key takeaways, corporate highlights, and future plans",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}